{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:18:39Z","timestamp":1792545519172,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.xops.2023.100440","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T08:52:42Z","timestamp":1701679962000},"page":"100440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["METformin for the MINimization of Geographic Atrophy Progression (METforMIN): A Randomized Trial"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1823-0854","authenticated-orcid":false,"given":"Liangbo Linus","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7118-1457","authenticated-orcid":false,"given":"Jeremy D.","family":"Keenan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1718-8419","authenticated-orcid":false,"given":"Noor","family":"Chahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abu Tahir","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8064-774X","authenticated-orcid":false,"given":"Jasmeet","family":"Saroya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7321-3793","authenticated-orcid":false,"given":"Chu Jian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2565-3353","authenticated-orcid":false,"given":"Daphne","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8982-322X","authenticated-orcid":false,"given":"Catherine","family":"Psaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7266-9868","authenticated-orcid":false,"given":"Jacquelyn","family":"Callander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9353-9862","authenticated-orcid":false,"given":"Christina","family":"Flaxel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9568-3558","authenticated-orcid":false,"given":"Amani A.","family":"Fawzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas K.","family":"Schlesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8496-0698","authenticated-orcid":false,"given":"Loh-Shan","family":"Bryan Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan C.","family":"Steinle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Telander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin R.","family":"Afshar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa D.","family":"Neuwelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7791-6998","authenticated-orcid":false,"given":"Jennifer I.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3061-3310","authenticated-orcid":false,"given":"Glenn","family":"Yiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1054-3423","authenticated-orcid":false,"given":"Jay M.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2023.100440_bib1","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.xops.2023.100440_bib2","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1097\/IAE.0000000000002182","article-title":"Histology of geographic atrophy secondary to age-related macular degeneration: a multilayer approach","volume":"38","author":"Li","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.xops.2023.100440_bib3","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.ophtha.2013.11.023","article-title":"Geographic atrophy: clinical features and potential therapeutic approaches","volume":"121","author":"Holz","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2023.100440_bib4","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/ICU.0000000000000746","article-title":"Emerging treatments for geographic atrophy in age-related macular degeneration","volume":"32","author":"Mahmoudzadeh","year":"2021","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.xops.2023.100440_bib5","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ophtha.2019.07.011","article-title":"Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial","volume":"127","author":"Liao","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2023.100440_bib6","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0140-6736(23)01583-0","article-title":"Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial","volume":"402","author":"Khanani","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.xops.2023.100440_bib7","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1210\/jc.2002-021688","article-title":"Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome","volume":"88","author":"Morin-Papunen","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.xops.2023.100440_bib8","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/j.1464-5491.2005.01632.x","article-title":"Metformin reduces C-reactive protein but not complement factor C3 in overweight patients with type 2 diabetes mellitus","volume":"22","author":"Carter","year":"2005","journal-title":"Diabet Med"},{"key":"10.1016\/j.xops.2023.100440_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/jcla.21803","article-title":"Relationship of the serum CRP level with the efficacy of metformin in the treatment of type 2 diabetes mellitus: a meta-analysis","volume":"30","author":"Shi","year":"2016","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.xops.2023.100440_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.838173","article-title":"Exploring the pharmacological potential of metformin for neurodegenerative diseases","volume":"14","author":"Du","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.xops.2023.100440_bib11","article-title":"Metformin protects ARPE-19 cells from glyoxal-induced oxidative stress","volume":"2020","author":"Qu","year":"2020","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.xops.2023.100440_bib12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/15353702211069986","article-title":"Metformin and retinal diseases in preclinical and clinical studies: insights and review of literature","volume":"247","author":"Amin","year":"2022","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.xops.2023.100440_bib13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/bcp.13780","article-title":"The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth","volume":"85","author":"Amin","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.xops.2023.100440_bib14","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.2337\/diabetes.49.12.2063","article-title":"Mechanism by which metformin reduces glucose production in type 2 diabetes","volume":"49","author":"Hundal","year":"2000","journal-title":"Diabetes"},{"key":"10.1016\/j.xops.2023.100440_bib15","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.2337\/dc08-1171","article-title":"Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis","volume":"31","author":"Bodmer","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.xops.2023.100440_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002967.pub3","article-title":"Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus","volume":"2010","author":"Salpeter","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.xops.2023.100440_bib17","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jamaophthalmol.2015.1440","article-title":"Association of geroprotective effects of metformin and risk of open-angle glaucoma in persons with diabetes mellitus","volume":"133","author":"Lin","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2023.100440_bib18","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1080\/09273948.2021.1872650","article-title":"Risk of non-infectious uveitis with metformin therapy in a large healthcare claims database","volume":"30","author":"Sobrin","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.xops.2023.100440_bib19","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9161039","article-title":"Metformin treatment is associated with a decreased risk of nonproliferative diabetic retinopathy in patients with type 2 diabetes mellitus: a population-based cohort study","volume":"2020","author":"Fan","year":"2020","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.xops.2023.100440_bib20","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.oret.2020.06.003","article-title":"Relationship between oral metformin use and age-related macular degeneration","volume":"4","author":"Stewart","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2023.100440_bib21","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/jamaophthalmol.2020.6331","article-title":"Association of metformin use with age-related macular degeneration: a case-control study","volume":"139","author":"Blitzer","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2023.100440_bib22","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/1649156","article-title":"Association between metformin and a lower risk of age-related macular degeneration in patients with type 2 diabetes","volume":"2019","author":"Chen","year":"2019","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.xops.2023.100440_bib23","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1167\/iovs.18-26422","article-title":"The common antidiabetic drug metformin reduces odds of developing age-related macular degeneration","volume":"60","author":"Brown","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2023.100440_bib24","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3349\/ymj.2019.60.7.679","article-title":"Effect of statins, metformin, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers on age-related macular degeneration","volume":"60","author":"Lee","year":"2019","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.xops.2023.100440_bib25","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1136\/bjophthalmol-2021-319641","article-title":"Metformin and risk of age-related macular degeneration in individuals with type 2 diabetes: a retrospective cohort study","volume":"107","author":"Gokhale","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.xops.2023.100440_bib26","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3389\/fnmol.2019.00102","article-title":"Rescue of retinal degeneration in rd1 mice by intravitreally injected metformin","volume":"12","author":"Luodan","year":"2019","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.xops.2023.100440_bib27","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1001\/jamaophthalmol.2022.5567","article-title":"Association of metformin with the development of age-related macular degeneration","volume":"141","author":"Domalpally","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2023.100440_bib28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ana.22006","article-title":"Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis","volume":"68","author":"Cree","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.xops.2023.100440_bib29","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.ophtha.2018.03.059","article-title":"Emixustat hydrochloride for geographic atrophy secondary to age-related macular degeneration: a randomized clinical trial","volume":"125","author":"Rosenfeld","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2023.100440_bib30","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamaophthalmol.2018.1544","article-title":"Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and Spectri phase 3 randomized clinical trials","volume":"136","author":"Holz","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2023.100440_bib31","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.oret.2020.03.019","article-title":"Orally administered alpha lipoic acid as a treatment for geographic atrophy: a randomized clinical trial","volume":"4","author":"Kim","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2023.100440_bib32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000510507","article-title":"Growth rate of geographic atrophy secondary to age-related macular degeneration: a meta-analysis of natural history studies and implications for designing future trials","volume":"64","author":"Wang","year":"2021","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.xops.2023.100440_bib33","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.oret.2020.12.002","article-title":"Geographic atrophy growth is strongly related to lesion perimeter: unifying effects of lesion area, number, and circularity on growth","volume":"5","author":"Shen","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2023.100440_bib34","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.oret.2018.01.019","article-title":"Natural history of geographic atrophy in untreated eyes with nonexudative age-related macular degeneration: a systematic review and meta-analysis","volume":"2","author":"Shen","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2023.100440_bib35","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/bjophthalmol-2020-317636","article-title":"Natural history of central sparing in geographic atrophy secondary to non-exudative age-related macular degeneration","volume":"106","author":"Shen","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.xops.2023.100440_bib36","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ophtha.2010.08.018","article-title":"Progression of geographic atrophy in age-related macular degeneration imaged with spectral domain optical coherence tomography","volume":"118","author":"Yehoshua","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2023.100440_bib37","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1001\/jamaophthalmol.2013.572","article-title":"Square root transformation of geographic atrophy area measurements to eliminate dependence of growth rates on baseline lesion measurements: a reanalysis of Age-Related Eye Disease Study report no. 26","volume":"131","author":"Feuer","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2023.100440_bib38","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1038\/s41598-022-08919-1","article-title":"A hierarchical Bayesian entry time realignment method to study the long-term natural history of diseases","volume":"12","author":"Shen","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.xops.2023.100440_bib39","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.oret.2020.03.020","article-title":"Progression of unifocal versus multifocal geographic atrophy in age-related macular degeneration: a systematic review and meta-analysis","volume":"4","author":"Shen","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2023.100440_bib40","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1097\/IAE.0000000000002480","article-title":"Reclassification of fundus autofluorescence patterns surrounding geographic atrophy based on progression rate: a systematic review and meta-analysis","volume":"39","author":"Shen","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.xops.2023.100440_bib41","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ajo.2006.11.041","article-title":"Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration","volume":"143","author":"Holz","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2023.100440_bib42","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ophtha.2013.09.044","article-title":"Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study","volume":"121","author":"Yehoshua","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2023.100440_bib43","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","article-title":"Novel method for analyzing snellen visual acuity measurements","volume":"30","author":"Gregori","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.xops.2023.100440_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J Stat Softw"},{"key":"10.1016\/j.xops.2023.100440_bib45","doi-asserted-by":"crossref","first-page":"264","DOI":"10.32614\/RJ-2022-022","article-title":"Power and sample size for longitudinal models in R\u2013the longpower package and shiny app","volume":"14","author":"Iddi","year":"2022","journal-title":"R J"},{"key":"10.1016\/j.xops.2023.100440_bib46","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.oret.2018.11.013","article-title":"Fellow eye status is a biomarker for the progression rate of geographic atrophy: a systematic review and meta-analysis","volume":"3","author":"Shen","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2023.100440_bib47","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1038\/s41433-023-02497-w","article-title":"Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial","volume":"37","author":"Patel","year":"2023","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.xops.2023.100440_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102786","article-title":"Metformin inhibits methylglyoxal-induced retinal pigment epithelial cell death and retinopathy via AMPK-dependent mechanisms: reversing mitochondrial dysfunction and upregulating glyoxalase 1","volume":"64","author":"Sekar","year":"2023","journal-title":"Redox Biol"},{"key":"10.1016\/j.xops.2023.100440_bib49","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0002-9343(97)00254-4","article-title":"Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial","volume":"103","author":"Garber","year":"1997","journal-title":"Am J Med"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914523001720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914523001720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T19:08:48Z","timestamp":1753816128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914523001720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2666914523001720"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2023.100440","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"METformin for the MINimization of Geographic Atrophy Progression (METforMIN): A Randomized Trial","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2023.100440","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Ophthalmology\u00e9","name":"copyright","label":"Copyright"}],"article-number":"100440"}}